Researchers from the Gladstone Institutes have developed a potential treatment for Type 1 diabetes by differentiating stem cells into insulin-producing pancreatic beta cells. These new cells, when transplanted into animal models, lowered abnormally high glucose levels down to a more healthy level in just one week.
The initial success of this research opens the door for similar treatment options to be developed for the 3 million Americans suffering from Type 1 Diabetes today. According to Dr Matthias Hebrok, one of the study’s authors, “Most immediately, this technology in human cells could significantly advance our understanding of how inherent defects in beta-cells result in diabetes, bringing us notably closer to a much-needed cure.”
Dental pulp stem cells [DPSC], due to their inherent plasticity, have successfully been differentiated into insulin-producing pancreatic stem cells. To learn more about the utility of dental pulp stem cells in emerging studies and regenerative therapies, and to learn how to bank your own valuable stem cells, visit www.StemSave.com or call 877-783-6728 (877-StemSave) today.
To view the full article, click here.
The Future of Regenerative Medicine is Now™.